- Center on Health Equity and Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Dr Jeff Patton on OCM PP3 Results, Challenges With the Model
Jeff Patton, MD, chief executive officer of Tennessee Oncology, discusses results from Oncology Care Model (OCM) performance period 3 (PP3) and challenges his practice still experiences with the model.
Jeff Patton, MD, CEO of Tennessee Oncology, discusses results from Oncology Care Model (OCM) performance period 3 (PP3) and challenges his practice still experiences with the model.
Transcript
With results from PP3 of the OCM now out, how did your results compare with PP2?
We have 4 pillars of trying to impact value in OCM; we do clinical pathways, we have nurse navigation, we have a triage platform, and we do palliative care. Through those, in each performance period, we’ve increased our savings. We’ve beat our benchmark every time, we’ve not hit the target, and so we haven’t had shared savings. But, every time, we’ve increased. PP3, we had 2.5% of savings. Now, if you remember, that includes the MEOS [Monthly Enhanced Oncology Services] payments, which is about 3%, so if you exclude the MEOS payments, we’ve saved 5.5% in the total cost of care. So, we’re excited about our results and going forward.
What are the most pressing challenges your practice still experiences with OCM and its reporting requirements?
You said it—the reporting requirements are probably the most onerous. We also think that risk stratification is not right and there’s some flaws there. And then the third and maybe the biggest is the novel therapy adjustment. If you’re an early adopter of a novel therapy, you get penalized. Even though there’s an adjustment, it’s an 80% adjustment, so by definition, you’re 20% in the hole with only an 80% adjustment. We think being penalized for being innovative is just not fair.
Award-Winning Poster Presentations From AMCP 2024
April 23rd 2024At the Academy of Managed Care Pharmacy (AMCP) 2024 annual meeting, multiple poster presentations concerned with health equity, data collection, glucagon-like peptide-1 agonists, and more were acknowledged for their originality, relevance, clarity, bias, and quality.
Read More
The Importance of Examining and Preventing Atrial Fibrillation
August 29th 2023At this year’s American Society for Preventive Cardiology Congress on CVD Prevention, Emelia J. Benjamin, MD, ScM, delivered the Honorary Fellow Award Lecture, “The Imperative to Focus on the Prevention of Atrial Fibrillation,” as the recipient of this year’s Honorary Fellow of the American Society for Preventive Cardiology award.
Listen
Standard Criteria for Loss of Ambulation Needed in DMD
April 19th 2024A recent study suggests the differences between ambulation definitions for patients with Duchenne muscular dystrophy (DMD) can impact the identification of ambulant vs nonambulant individuals, and standard criteria across settings are needed.
Read More
Promoting Equity in Public Health: Policy, Investment, and Community Engagement Solutions
June 28th 2022On this episode of Managed Care Cast, we speak with Georges C. Benjamin, MD, executive director of the American Public Health Association, on the core takeaways of his keynote session at AHIP 2022 on public health policy and other solutions to promote equitable health and well-being.
Listen
An Overview of Health Care and Pharmaceutical Trends, 2023-2024
April 19th 2024Douglas M. Long, BA, MBA, was featured as the keynote speaker on the closing day of The Academy of Managed Care Pharmacy 2024 annual meeting, with a session dedicated to surveying the health care and pharmaceutical trends of the last year.
Read More
